ACRP Announces TransCelerate's Intentions to Accept its Certification
Clinical research professionals who have a current CPI or CCRC designation will be able to use that as evidence that retaking GCP training is not necessary if they are working on a trial for one of the TransCelerate companies.
The ACRP announced that TransCelerate BioPharma is accepting its affiliate’s certifications for Certified Clinical Research Coordinator (CCRC®) and Certified Physician Investigator (CPI®) as evidence of Good Clinical Practice (GCP) training.
That TransCelerate’s membership companies are accepting these certifications to eliminate redundant GCP training for each and every new study team the coordinators or investigators join is not a surprise. This initiative to create efficiencies in the clinical trials process was one of the original five targets set forth in TransCelerate’s formation. Specifically, at that time it said of Site Qualification and Training , its goal was “To build upon the creation of common criteria for mutual recognition of GCP training and common forms to collect generic information about study sites, TransCelerate will provide a common framework to streamline the process for qualifying investigator sites, and standardizing non-protocol specific forms for clinical trials. The organization will also establish criteria for training site personnel new to clinical research and trials.”
The ACRP affiliate--the Academy of Clinical Research Professionals (the Academy)--have produced more than 28,500 certificants in more than 60 countries since 1992 (including the CPI, CCRC, and Certified Clinical Research Associate [CCRA®] programs.
At posting time, TransCelerate had not yet posted its release or comments. You can read the ACRP's full release here.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
